Pramipexole and Parkinson's disease, an update;Pramipexol y enfermedad de Parkinson, una actualización

Revista de Neurologia

Volumn 46, Issue 1, 2008, Pages 49-52

  Martinez Corral M ^a,b   Kulisevsky, Jaume ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Dopaminergic agonists; Parkinson's disease; Pramipexole; Treatment

Indexed keywords

BROMOCRIPTINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DROWSINESS; DRUG EFFECT; DRUG SUBSTITUTION; DYSAUTONOMIA; DYSKINESIA; DYSPEPSIA; EDEMA; HALLUCINATION; HUMAN; HYPOTENSION; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; PARKINSON DISEASE; PATIENT SELECTION; REVIEW; THERAPY EFFECT; TREMOR; VISUAL HALLUCINATION;

EID: 38549165154     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4601.2007643     Document Type: Review

References (28)

1. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997; 49: 724-8.
2. Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005; 20: 602-10.
3. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-53.
4. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006; 253: 601-7.
5. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004; 19: 656-62.
6. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007; 6: 826-9.
7. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA 1997; 278: 125-30.
8. Bonuccelli U. Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 2003; 16 (Suppl 1): S13-9.
9. Le WD, Jankovic J, Xie W, Appel SH. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 2000; 107: 1165-73.
10. Abramova NA, Cassarino DS, Khan SM, Painter TW, Bennett JP Jr. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SHSY5Y neuroblastoma. J Neurosci Res 2002; 67: 494-500.
11. Hall ED, Andrus PK, Oostveen JA, Althaus JS, VonVoigtlander PF. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996; 742: 80-8.
12. Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH. Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 2006; 96: 1315-21.
13. Izumi Y, Sawada H, Yamamoto N, Kume T, Katsuki H, Shimohama S, et al. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur J Pharmacol 2007; 557: 132-40.
14. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58: 11-7.
15. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-61.
16. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003; 60: 381-9.
17. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523-39.
18. Fedorova NV, Chigir IP. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease. Neurosci Behav Physiol 2007; 37: 539-46.
19. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-20.
20. Linazasoro G, Spanish Dopamine Agonists Study Group. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease. J Neurol 2004; 251: 335-9.
21. Navan P, Findley LJ, Undy MB, Pearce RK, Bain PG. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide. Eur J Neurol 2005; 12: 1-8.
22. Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. Mov Disord 2003; 18: 1324-31.
23. Pogarell O, Gasser T, Van Hilten JJ, Spieker S, Pollentier S, Meier D, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72: 713-20.
24. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, on behalf of Spanish Trapecio Study. A multicentric cross-sectional survey of the prevalence and correlates of neuropsychiatric symptoms in a population of Parkinson's disease without dementia. 58th Annual Meeting of the American Academy of Neurology. San Diego, 2006. Neurology 2006; 66 (Suppl 2): S124.
25. Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 2003; 26: 439-44.
26. Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging 2003; 20: 847-55.
27. Biglan KM, Holloway RG Jr, McDermott MP, Richard IH, Parkinson Study Group CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007; 69: 187-95.
28. Kleiner-Fisman G, Fisman DN. Risk factors for the development of pedal edema in patients using pramipexole. Arch Neurol 2007; 64: 820-4.